Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of ALLO-605 in Relapsed/Refractory Multiple Myeloma
NCT05000450Phase 2Terminated
- Sponsor
- Allogene Therapeutics
- Start
- Jun 2021
- Primary completion
- Oct 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ALLO-605 in multiple myeloma (MM), sponsored by Allogene Therapeutics. Primary endpoints: Dose Limiting Toxicities (ALLO-605) at 28 days, Dose Limiting Toxicities (ALLO-647) at 30 days and 1 more. Started Jun 2021; status: terminated.
02
Drugs
ALLO-605
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05000450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05000450.